Aicuris today announced positive results from its pivotal Phase 3 trial evaluating pritelivir in immunocompromised patients with refractory herpes simplex virus (HSV) infections. The results will be presented as an Oral Late Breaker presentation at the 2026 TANDEM Meetings on February 7, 2026, in Salt Lake City, USA. Pritelivir showed a significant superiority in lesion healing of 62.7% compared to 34.0% for ICT and demonstrated fewer treatment-emergent adverse events and drug-related discontinuations compared to standard-of-care therapies. This data will form the basis of a New Drug Application (NDA) submission to the U.S. FDA in Q1of 2026.

Aicuris Announces Pritelivir Phase 3 HSV Data to Be Presented as Late-Breaking Oral Presentation at Tandem Aicuris will share Phase 3 data from for its lead candidate pritelivir in immunocompromised patients with refractory herpes simplex virus infections, at the 2026 Tandem Meetings in Salt Lake City, USA.

Aicuris today announced the presentation of new clinical data at ID Week 2025, highlighting progress across two key antiviral programs. Phase 2 results for pritelivir showed a favorable safety profile and higher lesion healing rates compared to foscarnet in immunocompromised patients with HSV infections. These data supported FDA Breakthrough Therapy Designation and the design of the Phase 3 trial, which has recently met its primary endpoint. In addition, first-in-human Phase 1 data for AIC468 demonstrated favorable safety and pharmacokinetics, supporting further development for BK virus infections in kidney transplant recipients.

Aicuris today announced that the Phase 3 trial of its lead candidate pritelivir has met its primary and secondary endpoint. The aim of the trail was to evaluate the safety and efficacy of pritelivir compared to investigator’s choice in treating immunocompromised patients with refractory HSV infection, with or without resistance. Pritelivir demonstrated statistically significant superiority in lesion healing compared with standard-of-care treatments. These results will form the basis for regulatory filings with the FDA and globally.

Aicuris Announces Upcoming Oral and Poster Presentations at ID Week 2025 Aicuris will deliver two oral presentations on the clinical development of pritelivir, and a poster presentation of AIC468. The company’s medical team will also be available for in-person engagement at its booth throughout the conference.